Devyser announces today that, due to the newly-introduced "payback" levy in
Since 2014, Devyser has been operating in
"Obviously it's unfortunate when the goalposts are moved retrospectively and we are liable for a retroactive levy like this. In consultation with our legal advisers, we have thoroughly investigated and implemented the measures possible for us to avoid or reduce the imposed charge. We know that there are also a number of appeals against the decision. Based on the decision for the years 2015-2018 and our corresponding assessment for the years 2019-2022, a provision of
The amount in this press release is preliminary and unaudited. Devyser will not comment further on the financial development before the publication of the 2022 Year-end report.
Devyser's Year-end report for the period January-
This information is information that
For more information, please contact:
Fredrik Alpsten, CEO
Email: fredrik.alpsten@devyser.com
Tel: +46 706 673 106
Email: sabina.berlin@devyser.com
Tel: +46 739 519 502
About
Devyser develops, produces and sells genetic testing kits to laboratories in more than 50 countries. The products are used for complex DNA testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products simplify complex genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. The company was founded in 2004 and is based in
Devyser's shares are listed on the Nasdaq First North Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is
https://news.cision.com/devyser-diagnostics-ab/r/devyser-makes-provisions-due-to-retroactive--payback--levy,c3704612
(c) 2023 Cision. All rights reserved., source